Recent Updates
Recently added Catalysts
RADX Negative Sentiment Score: 40/100

RAD notifies end of share agreements with Lind Partners

Tuesday, July 16, 2024 1 min read
Key Takeaway: Radiopharm Theranostics has announced the termination of its share agreements with Lind Partners. This decision comes amidst ongoing clinical developments, including the dosing of the first patient in a Phase 1/2a clinical study for BetaBart (RV-01). The end of these agreements may raise concerns regarding the company's financial strategies and investor relations.

Market Sentiment Analysis

CONCERNS & RISKS

  • End of share agreements may indicate financial instability.
  • Potential loss of investor confidence due to the termination of agreements.

Full Press Release Details

• Announcements
• July 16, 2024
Loading Viewer…

More Announcements & Updates

• Announcements
• November 29, 2022
• Annual Reports
• September 30, 2024
• Announcements
• November 26, 2021
• Announcements
• November 25, 2024

Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)

Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026

Radiopharm Theranostics Provides Positive Clinical Updates Across Four Programs

CLINICAL UPDATE AND CAPITAL RAISING OCTOBER 20th, 2025

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Dr. Oliver Sartor Appointed to Radiopharm Scientific Advisory Board

• RAD Presentation June 2026
• Zacks Small-Cap Research 2026
• RAD Presentation March 2026
• Radiopharm Theranostics Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
• Zacks SCR Analysts Share Their Best Small-Cap Research Ideas for 2026
• Zacks Small-Cap Research

Frequently Asked Questions

What agreements did RAD terminate?

RAD terminated its share agreements with Lind Partners.

What is BetaBart (RV-01)?

BetaBart (RV-01) is a therapeutic candidate currently in a Phase 1/2a clinical study.

What are the implications of ending share agreements?

Ending share agreements may indicate financial instability and affect investor confidence.

When was the first patient dosed in the clinical study?

The first patient was dosed in the Phase 1/2a clinical study of BetaBart on October 20, 2025.

Tags: RADX Viatris Investor Conferences Healthcare Radiopharm Theranostics Lind Partners BetaBart Phase 1/2a clinical study
Last updated: Jul 16, 2024